This company develops FDA-approved pharmaceuticals, with a focus on broader therapeutic areas but currently has no active involvement in rare diseases or orphan drug designations.
0
Orphan Designations
7
FDA Approvals
Latest: ELREXFIO (2023)
0
Active Trials
0
Rare Diseases
0
News (30d)
Quiet
U.S. Pharmaceuticals is a company with 0 orphan drug designations across 0 rare diseases, including 7 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
No pipeline data available yet.